Integrated CDMO for small-molecule APIs and chiral amino acids across three continents
Flamma is a 1,000+-person CDMO operating three manufacturing sites (Italy, US, China) with 1,300 m³ of total capacity, specializing in cGMP small-molecule APIs, chiral amino acids, and peptide-related intermediates. Active hiring across manufacturing, engineering, and operations—with a mid-to-junior hiring skew—suggests scaling production capacity. Current project portfolio emphasizes process automation (DCS updates, equipment installation), regulatory tightening (life-cycle assessments, carbon footprinting), and throughput optimization (QC expansion, downtime reduction).
Flamma is a family-owned CDMO headquartered near Milan, Italy, serving pharmaceutical and biotech companies across early-stage development through commercial manufacturing. The company operates two facilities in Italy (900 m³ capacity) and one in Dalian, China (400 m³), with a US development lab outside Philadelphia for small-scale (gram to kilogram) work. Core offerings center on cGMP manufacturing of small-molecule APIs, novel chemical entities, reference standards, advanced intermediates, and high-value chiral materials—especially amino acid derivatives used in peptide therapeutics. Flamma handles the entire drug lifecycle: process R&D, preclinical scale-up, and multi-ton commercial production.
Flamma manufactures cGMP small-molecule APIs, novel chemical entities, reference standards, and chiral amino acid materials for peptide drugs. Scale ranges from gram-to-kilogram (US lab) to hundreds of kilograms to multi-ton (Italy and China facilities).
Flamma headquarters is in Chignolo d'Isola, near Milan, Italy. The company operates two Italian sites (900 m³ combined capacity), a US facility near Philadelphia for development work, and a 100%-owned facility in Dalian, China (400 m³).
Other companies in the same industry, closest in size